S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

from Treating Together · host Targeted Oncology

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Episode metadata supplied by the publisher feed · Published Mar 15, 2024

Embed this episode

Attribution link and audio player

Ready to play

S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

0:00 22:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Treating Together?

This episode is 22 minutes long.

When was this Treating Together episode published?

This episode was published on March 15, 2024.

Can I download this Treating Together episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!